{
    "clinical_study": {
        "@rank": "48654", 
        "acronym": "IVIG", 
        "arm_group": {
            "arm_group_label": "Immune Globulin", 
            "arm_group_type": "Experimental", 
            "description": "Immunoglobulin G Deficiency Associated with persistent asthma subtypes"
        }, 
        "brief_summary": {
            "textblock": "Immunoglobulin G deficiency subtypes in patients with asthma six months once a month\n      intravenous immunoglobulin (400mg/kg/4weeks) infection in treatment-related effect on\n      reducing the frequency of asthma exacerbations appreciate."
        }, 
        "brief_title": "IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": [
                "Asthma", 
                "IgG Deficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients Registration\n\n      \u2022It is required to ensure that the patients meet the inclusion criteria for this clinical\n      trial, are free from any items of exclusion criteria, are explained about the participation\n      in the clinical trial along with the informed consent forms.\n\n      Procedure\n\n      \u2022six months once a month intravenous immunoglobulin (400mg/kg/4weeks)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient from over 16 years to under 75 years\n\n          -  Patients diagnosed with asthma over six months ago\n\n          -  immunoglobulin G subtypes who were diagnosed with immune deficiency\n\n          -  more than 2 years Upper and lower respiratory tract infections\n\n             , and asthma exacerbations in this regard.\n\n          -  \u2460 calculated creatinine clearance \u2267 50ml/min\n\n               -  ALT and AST <x 3 times the upper limit of normal\n\n                    -  ALP <x 3 times the upper limit of normal\n\n                         -  total bilirubin <x 1.5 times the upper limit of normal\n\n        Exclusion Criteria:\n\n          -  within six months of the onset of the experiment who received immunoglobulin therapy\n\n          -  immune globulin for those with a history of hypersensitivity reactions\n\n          -  six months ago, another clinical trial participants.\n\n          -  Systemic steroids and immunomodulators, such as asthma control that may affect the\n             resources required drug administration.\n\n          -  pregnant or lactating women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01992328", 
            "org_study_id": "MED-CT4-12-405"
        }, 
        "intervention": {
            "arm_group_label": "Immune Globulin", 
            "description": "6 months once a month intravenous immunoglobulin (400mg/kg/4weeks)", 
            "intervention_name": "Immune Globulin", 
            "intervention_type": "Drug", 
            "other_name": "Immunoglobulin G Deficiency"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Immunoglobulin G", 
                "Antibodies", 
                "Immunoglobulins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Immunoglobulin G Deficiency", 
        "lastchanged_date": "November 19, 2013", 
        "number_of_arms": "1", 
        "official_title": "IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency", 
        "overall_contact": {
            "email": "FORSAKE326@ajou.ac.kr", 
            "last_name": "yun-kyoung KIM", 
            "phone": "82-31-219-4467"
        }, 
        "overall_official": {
            "affiliation": "Department of medicine, Ajou University School of Medicine", 
            "last_name": "hae-sim park", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "6 months after treatment compared to before treatment 6 months", 
            "measure": "Infection rate", 
            "safety_issue": "No", 
            "time_frame": "6months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01992328"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ajou University School of Medicine", 
            "investigator_full_name": "Hae-Sim Park", 
            "investigator_title": "Professor, Department of medicine, Ajou University School of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "- Lung function (FEV1) compared", 
                "measure": "lung funtion", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "- Systemic steroid dose and the number of uses", 
                "measure": "steroid", 
                "safety_issue": "No", 
                "time_frame": "6 months af"
            }, 
            {
                "description": "- The frequency and duration of antibiotic", 
                "measure": "antibiotic", 
                "safety_issue": "No", 
                "time_frame": "6months"
            }, 
            {
                "description": "- The frequency of asthma exacerbations", 
                "measure": "asthma syptoms", 
                "safety_issue": "No", 
                "time_frame": "6months"
            }, 
            {
                "description": "- Asthma Quality of Life (AQOL)", 
                "measure": "Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "6months"
            }, 
            {
                "description": "- Asthma control score (K-ACT)", 
                "measure": "Questionnair", 
                "safety_issue": "No", 
                "time_frame": "6months"
            }, 
            {
                "description": "- Before and after treatment serum IgG subclass", 
                "measure": "IgG subclass", 
                "safety_issue": "No", 
                "time_frame": "6months"
            }, 
            {
                "description": "- Cytokines serum levels before and after treatment", 
                "measure": "Cytokines", 
                "safety_issue": "No", 
                "time_frame": "6months"
            }, 
            {
                "description": "- The frequency of adverse events", 
                "measure": "adverse events", 
                "safety_issue": "No", 
                "time_frame": "6months"
            }
        ], 
        "source": "Ajou University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ajou University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}